Q&A Session at 2022 Annual General Meeting

Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems' board of directors answer questions from…


Results of 2022 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual…


Presentation Visuals from 25th May 2022 Annual General Meeting

The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here.    …


Chairman’s Address to Shareholders at 2022 Annual General Meeting

Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my…


Ticker News Interview - Breast Cancer Clinical Trial Update

Bob Proulx discusses updates on the first-in-human MagSense® HER2 breast cancer clinical trial with TickerTV - trial is progressing positively.  …


Imagion Biosystems April 2022 Investor Newsletter

We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap…


MagSense® HER2 Breast Cancer First-in-human Study Progress Update

Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging…


Imagion Biosystems 2021 Full Year Results

Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below. 2021 Clinical Highlights:  Multiple…


Quarterly Activity Report and Appendix 4C for 31 December 2021

Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the…


Application for quotation of +securities

The document "Application for quotation of +securities" was lodged with ASX on 6th January, 2022. Please click to review the full announcement at ASX.